Baltimore's beloved live music tradition, Jazzy Summer Nights is well into its 25th and final season. This farewell season, ...

Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A ...

Clinigen, the global pharmaceutical services Group, has appointed seasoned biopharma executive Paul Carter as Non-Executive Chair of its Board. This move strengthens the Board as Clinigen advances its ...

Gilead Sciences, Inc. (NASDAQ: GILD) is one of the. The company announced that the US FDA approved Yeztugo ® (lenacapavir), ...

The July 24 event aims to inspire accessible and impactful philanthropy by breaking down barriers to meaningful change.

A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following ...

This article discusses the DOJ’s growing crackdown on healthcare fraud, focusing on illegal speaker programs like Gilead’s $202 million settlement. It stresses the importance of strong compliance, ...

As Gilead Sciences gets underway with the key launch of its twice-yearly pre-exposure prophylaxis (PrEP) HIV med, the company ...

Is the cost of research aimed at curing HIV worth it, when HIV can be effectively managed and prevented by existing drugs?

On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc.

Gilead Sciences (GILD) closed the most recent trading day at $110.67, moving +2.83% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.52%. Elsewhere, the Dow saw an ...

The U.S. Supreme Court preserved the U.S. Preventative Services Task Force coverage mandate that requires payers to cover ...